Merck’s shares have climbed 41% over the past six months, fueled by a combination of steady top-line growth and a pronounced expansion in profitability. In its most recent quarter, revenue rose 4% year-over-year to $15.5 billion, while net income jumped 22% to $5.2 billion, reflecting margin improvements in both its human health and Animal Health segments. Investor confidence has also been bolstered by upbeat commentary from institutional analysts, with five major brokerages raising their earnings forecasts for 2026 by an average of 8%.

With Keytruda’s blockbuster performance well established, Merck is shifting market focus to its emerging non-oncology franchises. Analysts expect the newly launched Capvaxive vaccine to contribute $200 million in Q4 sales, while Winrevair, its inhaled therapy for chronic respiratory disease, is forecast to generate $150 million. Meanwhile, Merck’s Animal Health business—responsible for roughly 12% of total revenues—reported a 6% sales gain in Q3 and is projected to maintain double-digit growth driven by new equine and livestock product rollouts in North America and Europe.

Merck’s board has declared a quarterly dividend of $0.85 per share for the second quarter of 2026, payable April 7 to shareholders of record as of March 16. This represents a 3% increase from the prior payout and marks Merck’s 16th consecutive annual dividend hike. At its current payout ratio of approximately 30% of trailing free cash flow, the dividend remains comfortably covered while preserving room for further capital deployment into research and development.